对低氧瘤的剂量-输送时间的生物剂量测量影响,使用修改的微剂量测量运动模型
Daisuke Kawahara1, Yasushi Nagata1
1Department of Radiation Oncology, Institute of Biomedical & Health Science, Hiroshima University, Japan.
概括
这项研究改进了一种微剂量测量运动模型 (MKM),用于评估缺氧瘤中的放射生物效应. 较短的辐射传递时间和较高的氧气水平提高了细胞杀死,特别是每小部分的剂量较高.
科学领域:
- 医学物理 医学物理
- 辐射瘤学 辐射瘤学
- 放射生物学的放射生物学
背景情况:
- 微剂量测量动力模型 (MKM) 已得到改进,以考虑延长剂量递送时间.
- 现有的模型没有充分考虑氧气对放射生物效应的影响.
- 这项研究的重点是评估光子辐射治疗期间缺氧瘤的生物剂量效应.
研究的目的:
- 用改进的MKM来评估低氧瘤中剂量递送时间的生物剂量测量效应.
- 为了纳入氧气水平对辐射治疗结果的影响.
- 在具有挑战性的瘤微环境中提高生物剂量估计的准确性.
主要方法:
- 细胞存活率在无氧,缺氧和有氧条件下使用蒙特卡洛代码PHITS进行评估.
- 微剂量测量运动模型用于估计各种剂量速率 (0.5-24 Gy/min) 的生物剂量 (Dbio).
- 模拟改变了每分数的剂量 (2-20 Gy) 和瘤氧气部分压力 (pO2:0.01-5.0%).
主要成果:
- 不同剂量速率的生物剂量比率 (RDR) 随着剂量增加而增加,在24 Gy/min时达到1.13
- 在不同氧度 (Roxy) 的生物剂量比率显示出显著的变化,在2%pO2时最多为0.96.
- 生物剂量受到氧气度的显著影响,特别是在较低的pO2水平.
结论:
- 开发的模型准确地估计了临床场景的低氧条件下的细胞杀死和生物剂量.
- 减少剂量递送时间和增加氧化增强了放射生物效应.
- 研究结果表明,在低氧环境中,当使用较短的输送时间时,每小部分的更高剂量更有效.
相关概念视频
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
01:06Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
82
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
82
01:20Pharmacokinetic Models: Overview
746
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
746
01:26Pharmacokinetic Models: Comparison and Selection Criterion
88
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
88